[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Zhejiang Chinese Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":343},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,67,96,125,147,174,199,220,246,268,290,309,324],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100632471","electroacupuncture-with-two-pulse-patterns-for-bells-palsy-using-surface-electromyography-evaluation-100632471",false,"NCT07514117","Electroacupuncture With Two Pulse Patterns for Bell's Palsy Using Surface Electromyography Evaluation","Electroacupuncture With Different Pulse Patterns for the Post-acute Phase of Bell's Palsy: a Study Protocol for a Randomized Controlled Trial With Surface Electromyography Evaluation","EABP-SEMG","Inclusion Criteria:\n\n* diagnosed clinically as BP, with imaging evidence (brain CT and\u002For MRI) excluding central nervous system lesions associated with facial palsy\n* the disease duration of 21 days to 6 months, inclusive\n* age 18-70 years\n* voluntary participation and provision of written informed consent\n\nExclusion Criteria:\n\n* facial paralysis caused by other diseases\n* have previous history of facial paralysis\n* present with facial muscle spasm, synkinesis or contracture\n* diagnosed as Ramsey-Hunt Syndrome\n* history of surgery on face\n* with cardiac pacemakers implanted\n* pregnant or lactating patients\n* along with other severe uncontrolled diseases, recognition disorder, aphasia or mental disorders\n* present with bilateral facial paralysis","ALL","18 Years","70 Years",{"count":21,"type":22},111,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial is designed to evaluate the therapeutic effects of two EA parameter settings for Bell's palsy and to investigate the electromyographic characteristics of the disease. The main questions it aims to answer are:\n\n* Can continuous pulse pattern and intermittent pulse pattern of EA improve the symptoms of Bell's palsy?\n* Do continuous pulse pattern and intermittent pulse pattern of EA impact the electromyographic characteristics of facial muscles in patients with Bell's palsy? The researchers will evaluate the effects of continuous pulse pattern and intermittent pulse pattern in treating Bell's palsy by using surface electromyography as an objective indicator of assessment. The trial lasts for 4 weeks and the treatment period lasts for 4 weeks.\n\nParticipants will:\n\n* receive sham EA, EA with a continuous pulse pattern or EA with an intermittent pulse pattern for 3 times weekly for 4 weeks (12 sessions in total).\n* receive assessment of symptom severity and social functioning on Day 0, end of week 2, end of week 4.",[28],"Bell Palsy",[30,31,32,33],"Bell's palsy","surface electromyography","randomized controlled trial","electroacupuncture","NOT_YET_RECRUITING","2026-04-27",{"date":37,"type":38},"2026-04-30","ACTUAL",{"date":40,"type":22},"2026-05",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"The First Affiliated Hospital of Zhejiang Chinese Medical University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100635364","effect-of-low-frequency-electroacupuncture-on-diabetic-peripheral-neuropathy-100635364","NCT07551726","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- 1.Aged 18-70 years, with no restriction on disease duration or sex. 2.Met the diagnostic criteria for DPN, evidenced by: decreased NCV on lower-limb electroneurography, and\u002For persistent pain and\u002For sensory abnormalities in the limbs (at least in both lower limbs), with diminished ankle reflex (unilateral or bilateral) and reduced vibration sense, and a Toronto Clinical Scoring System (TCSS) score ≥ 6.\n\n3.Able to communicate effectively. 4.No severe systemic medical conditions (e.g., cardiac, cerebral, hepatic, or renal disorders), severe psychiatric illnesses, or cognitive impairment.\n\n5.Mentally competent, voluntarily agree to participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* 1.Peripheral neuropathy due to other etiologies (e.g., hypothyroidism, alcohol, medications, hereditary causes), presence of limb ulcers or gangrene, or a history of skin ulceration or poorly healing lesions.\n\n  2.Severe comorbid conditions, including renal, cardiovascular, cerebrovascular, pulmonary, or hepatic diseases, infectious diseases, malignancies, or severe psychiatric disorders.\n\n  3.History of knee\u002Fhip replacement surgery or lower limb fracture within the past 3 months, or any other condition that could interfere with the assessment of neuropathy.\n\n  4.Received acupuncture or moxibustion treatment specifically for DPN within the past 3 months.\n\n  5.Concurrent participation in another interventional clinical trial. 6.Women who are planning pregnancy, are pregnant, or are lactating. 7.Unwillingness to be randomized to either the waitlist (WL) or EA group. 8.Chronic abuse of opioids, analgesics, illicit drugs, or alcohol.",{"count":54,"type":22},92,[25],"Diabetic peripheral neuropathy (DPN) is a common and disabling complication of diabetes. Many patients experience pain, numbness, and impaired quality of life, while currently available treatments may have limited benefit or cause adverse effects. Electroacupuncture (EA) may provide a safe, non-pharmacological treatment option, but further clinical evidence is needed.\n\nThe purpose of this study is to evaluate the efficacy and potential mechanisms of low-frequency (2 Hz) electroacupuncture in patients with DPN. In this prospective, randomized, sham-controlled trial, participants will be assigned to either a verum 2 Hz EA group or a sham EA group. The study will assess nerve conduction velocity, pain intensity, serum neurotrophic factors and inflammatory cytokines, and quality of life.\n\nThis study is intended to provide clinical evidence on the use of low-frequency EA for DPN and to examine whether its effects are related to neurotrophic and inflammatory pathways.",[58,59],"Diabetic Peripheral Neuropathy (DPN)","Electroacupuncture","2026-04-20",{"date":35,"type":38},{"date":63,"type":22},"2026-04-26",{"date":65,"type":22},"2027-12-31",{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100634264","the-efficacy-of-intradermal-acupuncture-for-ocular-surface-diseases-after-intractable-facial-paralysis-100634264","NCT07537426","The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis","Inclusion Criteria:\n\n* 1.Male or female patients aged 18-65 years.\n* 2.Meets diagnostic criteria for intractable peripheral facial paralysis, with disease duration from 1 month to 1 year. FNGS 2.0 ≥15 points; ENoG shows the ratio of CMAP amplitude≤ 20%.\n* 3.At least one subjective ocular symptom (dryness, foreign body sensation, burning, fatigue, redness, fluctuating vision) and OSDI scores between 30 and 80.\n* 4.Voluntarily provides written informed consent and can comply with treatment and follow-up.\n\nExclusion Criteria:\n\n* 1.Other ocular diseases (glaucoma, keratitis, retinopathy, acute inflammation of conjunctiva, sclera, cornea).\n* 2\\. Intraocular surgery or laser therapy within the past 90 days.\n* 3.Use of systemic or topical antibiotics or tear-affecting drugs within 3 weeks; dry eye medications within 2 weeks.\n* 4.Lacrimal passage obstruction, dacryocystitis, punctal occlusion, or neurological impairment preventing full eyelid closure.\n* 5.Coagulation disorders, open wounds, or local infection at intervention sites.\n* 6.Allergy to press-needle materials (stainless steel, adhesive tape).\n* 7.Pregnancy or lactation.\n* 8.Severe cardiac, hepatic, renal, psychiatric disorders, or malignant tumors.\n* 9.Participation in another clinical trial within the past month.","65 Years",{"count":75,"type":22},78,[25],"The purpose of this study is to explore the clinical efficacy of intradermal acupuncture in the treatment of ocular surface diseases after Intractable Facial Paralysis, and to seek effective and convenient treatment for ocular surface diseases after intractable peripheral facial paralysis. The main question it aims to answer is ： Will the intradermal acupuncture intervention effectively reduce the OSDI score ? The researchers compared the intradermal acupuncture with the placebo-needle to observe whether the intradermal acupuncture could better improve the symptoms.",[79,80,81],"Facial Paralysis, Peripheral","Bell's Palsy","Ocular Surface Disease",[83,84,85],"sequelae of facial paralysis","ocular surface disease","intradermal acupuncture","RECRUITING","2026-04-12",{"date":89,"type":38},"2026-04-17",{"date":91,"type":38},"2026-04-01",{"date":93,"type":22},"2028-03-25",{"name":44,"class":45},1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":95},"100626984","auricular-stimulation-for-functional-dyspepsia-with-insomnia-efficacy-and-mechanisms-100626984","NCT07442734","Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms","Study on the Efficacy and Mechanism of Auricular Stimulation for Functional Dyspepsia With Insomnia Based on Brain Function: A Single-center, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for functional dyspepsia and sleep disorders (25,26)\n* Pittsburgh Sleep Quality Index score ≥7\n* Right-handed, aged 18 years or above\n* Have not taken the following medications for at least 2 weeks prior to enrollment: antibiotics (oral, intramuscular, or intravenous), microbiota-related products (probiotics, prebiotics, and synbiotics, etc.), or any drugs affecting gastrointestinal flora, any drugs or supplements that improve sleep quality or suppress neural activity in the brain, medications related to functional dyspepsia treatment, or other related therapies\n* Agree to voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Secondary insomnia caused by drugs or other diseases\n2. Comorbidity with other psychiatric disorders, or severe heart, liver, kidney, or other systemic diseases\n3. Previously received this treatment method or participated in other clinical trials within the past 6 months\n4. Presence of contraindications to auricular therapy, such as allergy to skin preparation or damage at the auricular application site\n5. Pregnant or breastfeeding women\n6. History of cranial organic lesions, cranial surgery, or severe trauma",{"count":104,"type":22},176,[25],"Functional dyspepsia (FD) is a chronic disorder of gut-brain interaction characterized by bothersome upper abdominal symptoms arising from the gastroduodenal region. Diagnosis is made after clinical evaluation has excluded structural disease that could explain symptoms (e.g., upper gastrointestinal endoscopy). According to Rome IV criteria, FD is categorized into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), with symptom overlap commonly observed. FD is prevalent worldwide and is associated with substantial impairment in health-related quality of life and a significant socioeconomic burden.\n\nSleep disturbance, anxiety, and depression are frequent in FD and are associated with symptom severity and recurrence. Current management-such as prokinetic agents, acid-suppressive therapy, and psychotropic medications when indicated-can be limited by variable efficacy, adverse effects, and concerns regarding long-term use. The pathophysiology of FD is multifactorial and incompletely understood; increasing evidence highlights dysregulation of the brain-gut axis and autonomic nervous system function (12,13). Auricular vagus nerve-related stimulation may influence brainstem neurotransmission, gastric tone\u002Fmotility, and mood (14), suggesting a potentially safe, non-pharmacological approach for FD with comorbid sleep problems. However, the mechanistic links among autonomic regulation, gut microbiota\u002Fshort-chain fatty acids, and FD remain uncertain.\n\nThis study aims to evaluate the clinical efficacy and safety of auricular acupoint stimulation in FD patients with sleep disorders and to explore underlying mechanisms using brain-function assessments together with autonomic and gastrointestinal-related measures.",[108,109,110],"Functional Dyspepsia","Insomnia","Brain and Nervous System",[112,108,113,114,115,116],"Auricular Acupressure","insomnia","clinical efficacy","Effect mechanism study","Brain functional areas","2026-02-24",{"date":119,"type":38},"2026-03-02",{"date":121,"type":38},"2025-10-30",{"date":123,"type":22},"2026-10-01",{"name":44,"class":45},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":95},"100625510","early-phase-1-clinical-study-of-anti-cd19bcma-universal-chimeric-antigen-receptor-t-cells-ucar-t-in-the-treatment-of-refractory-idiopathic-membranous-nephropathy-imn-100625510","NCT07423572","Clinical Study of Anti-CD19\u002FBCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)","Inclusion Criteria:\n\n1. Aged 18 to 75 years inclusive, either gender;\n2. Adequate function of major organs as defined below:\n\n   1. Absolute neutrophil count ≥ 1.0 × 10⁹\u002FL, hemoglobin ≥ 60 g\u002FL, platelet count ≥ 50 × 10⁹\u002FL;\n   2. Hepatic function: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; total bilirubin (TBIL) ≤ 1.5 × ULN;\n   3. Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, prothrombin time (PT) ≤ 1.5 × ULN;\n   4. Cardiac function: hemodynamically stable, left ventricular ejection fraction (LVEF) ≥ 50%;\n3. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must use a medically acceptable contraceptive method or practice abstinence during study treatment and for at least 6 months after the end of treatment.Female subjects of childbearing potential must have a negative serum HCG test within 7 days prior to enrollment and must not be breastfeeding;\n4. Voluntarily agree to participate in this clinical study, provide written informed consent, demonstrate good compliance, and be willing to comply with follow-up procedures;\n5. Diagnosis of primary membranous nephropathy confirmed by renal biopsy pathology;\n6. Meet the clinical criteria for high-risk or relapsed\u002Frefractory membranous nephropathy, defined as:\n\n   High-risk patients meeting any of the following:\n   1. Estimated glomerular filtration rate (eGFR, CKD-EPI equation) \\\u003C 60 mL\u002Fmin\u002F1.73 m², and\u002For urinary protein \\> 8 g\u002Fday for ≥ 6 months;\n   2. Normal eGFR, urinary protein \\> 3.5 g\u002Fday despite ACEI\u002FARB treatment for 6 months with \\\u003C 50% reduction in proteinuria, plus serum albumin \\\u003C 25 g\u002FL or anti-PLA2R antibody (aPLA2R) \\> 50 RU\u002FmL; Refractory membranous nephropathy: inadequate response or resistance to prior immunosuppressive therapy (including corticosteroids and\u002For cytotoxic agents, immunosuppressants and\u002For biologics), defined as persistent urinary protein ≥ 3.5 g\u002Fday with \\\u003C 50% reduction from baseline; Relapsed membranous nephropathy: recurrence (24-hour urinary protein ≥ 3.5 g) after achieving complete or partial remission (CR\u002FPR) following treatment;\n7. For relapsed\u002Frefractory membranous nephropathy patients during screening: eGFR ≥ 45 mL\u002Fmin\u002F1.73 m².\n\nExclusion Criteria:\n\n1. Subjects with known allergic reaction, hypersensitivity, intolerance, or contraindication to CD19\u002FBCMA universal CAR-T or any components of the study drugs (including fludarabine, cyclophosphamide, and tocilizumab), or a history of severe allergic reaction in the past.\n2. Presence or suspicion of uncontrolled or treatable fungal, bacterial, viral, or other infections.\n3. Central nervous system diseases caused by autoimmune or non-autoimmune diseases (including epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis).\n4. Subjects with severe cardiac diseases, such as angina pectoris, myocardial infarction, heart failure, arrhythmia, etc.\n5. Subjects with congenital immunoglobulin deficiency.\n6. Subjects with other malignant tumors (excluding non-melanoma skin cancer and carcinoma in situ of the cervix, bladder, or breast with disease-free survival \\> 5 years).\n7. Subjects with end-stage renal failure.\n8. Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with HBV DNA titer above the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and HCV RNA; subjects positive for human immunodeficiency virus (HIV) antibody; subjects with positive syphilis test.\n9. Subjects with psychiatric disorders and severe cognitive impairment.\n10. Subjects who participated in other clinical trials within 6 months prior to enrollment.\n11. Pregnant or lactating females, or females intending to become pregnant during the study.\n12. Subjects with hypertension or diabetes mellitus that cannot be controlled by medication.\n13. Subjects for whom the investigator considers there are other reasons for ineligibility.\n14. Secondary membranous nephropathy (e.g., associated with hepatitis B, systemic lupus erythematosus, drug-related, malignancy-related, etc.), or concurrent renal disease confirmed by renal biopsy.\n15. Type 1 or type 2 diabetes mellitus.","75 Years",{"count":133,"type":22},18,[135],"EARLY_PHASE1","A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19\u002FBCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)",[138],"Refractory Idiopathic Membranous Nephropathy","2026-02-14",{"date":141,"type":38},"2026-02-20",{"date":143,"type":22},"2026-02-28",{"date":145,"type":22},"2029-09-28",{"name":44,"class":45},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":173,"locationsCount":95},"100623285","transcutaneous-auricular-vagus-nerve-stimulation-for-prevention-of-emergence-agitation-and-delirium-in-children-undergoing-tonsillectomy-and-adenoidectomy-100623285","NCT07394647","Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Emergence Agitation and Delirium in Children Undergoing Tonsillectomy and Adenoidectomy","Transcutaneous Auricular Vagus Nerve Stimulation for Preventing Emergence Agitation and Delirium After Pediatric Tonsillectomy and Adenoidectomy: A Randomized, Double-Blind, Interventional Study","Inclusion Criteria:\n\n* Children aged 3 to 8 years.\n* Patients receiving care at The First Affiliated Hospital of Zhejiang Chinese Medical University with a diagnosis of tonsil and\u002For adenoid hypertrophy, scheduled for tonsillectomy and\u002For adenoidectomy under sevoflurane inhalation general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Ability to understand the study procedures and assessment scales, and to communicate effectively with study personnel.\n\nExclusion Criteria:\n\n* ASA physical status III-IV, or presence of hepatic or renal dysfunction, cardiovascular disease, or endocrine disorders.\n* Neuromuscular disorders or dermatitis of the left auricle.\n* Recent respiratory infection, developmental delay, or autism spectrum disorder.\n* Receipt of specialized care, residence in social welfare institutions, or any other condition that may interfere with study participation.\n* Current enrollment in another clinical trial.","3 Years","8 Years",{"count":157,"type":22},120,[25],"Brief Summary This study is designed to find out whether transcutaneous auricular vagus nerve stimulation (taVNS) can safely reduce restlessness and confusion when children wake up from anesthesia after tonsillectomy and adenoidectomy. These problems, called emergence agitation and delirium, are common after surgery and can cause distress for both children and their families.TaVNS is a non-invasive treatment that delivers mild electrical stimulation to a specific area of the ear connected to the vagus nerve. It does not involve needles or medication, and children usually feel only a gentle tingling sensation.In this randomized, double-blind study, children will be assigned by chance to receive either taVNS or a sham (placebo) stimulation during surgery. Neither the children, their families, nor the medical team providing care will know which treatment each child receives.Researchers will observe and record how calmly children wake up from anesthesia, whether they show signs of delirium, and any side effects. The goal of this study is to test whether taVNS is an effective and safe way to improve recovery and comfort for children after surgery.",[161,162],"Emergence Agitation","Emergence Delirium",[164,161,162,165,166],"Pediatric","taVNS","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","2026-02-01",{"date":169,"type":38},"2026-02-06",{"date":117,"type":22},{"date":172,"type":22},"2026-12-30",{"name":44,"class":45},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":95},"100555611","early-phase-1-evidence-based-evaluation-and-mechanism-of-shenhuang-granules-in-the-treatment-of-sepsis-100555611","NCT06514339","Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis","Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis: a Randomized, Double-blind, Placebo-controlled, Effective Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years old\n* Meet the diagnostic criteria of sepsis 3.0 guidelines\n* Sign informed consent.\n\nExclusion Criteria:\n\n* Liver or kidney single SOFA score ≥3 points of liver and kidney dysfunction\n* Death is expected within 48 hours, or SOFA≥15 points, or APACHE II ≥30 points, or the patient refuses active treatment\n* Patients with allergic reactions to traditional Chinese medicine\n* Patients treated with chemotherapy or radiotherapy or high-dose immunosuppressants within the last 1 month\n* Participants in other clinical trials at the same time or within 30 days\n* Pregnant and lactating women\n* Patients with severe gastrointestinal bleeding, intestinal obstruction, or severe intraperitoneal pressure elevation (IAP≥20mmHg).",{"count":182,"type":22},410,[135],"Sepsis is a life-threatening organ dysfunction caused by the body's dysfunctional response to infection, most patients require treatment in the ICU, and is the leading cause of death worldwide. Over the years, the development of new drugs for the treatment of sepsis has failed without significant benefit in reducing mortality, and there is currently no effective drug treatment. Therefore, sepsis is a serious disease threatening the life and health of patients, causing a huge burden to society, and is a major problem in the medical field.\n\nThe pathogenesis of sepsis is complicated, and immune imbalance is the key mechanism. Suppression of host immune function may be the root cause of the increase in the long-term mortality of sepsis. Bidirectional immune regulation may be an important treatment plan to improve the survival rate and quality of life of sepsis patients. In recent years, the contribution of traditional Chinese medicine to sepsis has been highly valued at home and abroad. The treatment of sepsis by traditional Chinese medicine mainly plays the role of bidirectional immune regulation by dispelling the evil and supporting the right. Our team has achieved some results in the diagnosis and treatment of sepsis by using traditional Chinese medicine. Supported by National Natural Science Foundation of China (81774070). The team also found that magnolol can inhibit intestinal mucosal inflammation in sepsis, which was also supported by the National Natural Science Foundation of China (82174178). The team of Qhuang scholars inherit the academic experience of Zhu Liangchun, the master of Chinese medicine, warm and hot disease need not be limited to the law of wei, qi, ying, blood transmission, that is, the disease can be solved both outside and inside, breaking the three bans of warm and cold disease. On the basis of inheriting Zhu Liangchun's academic theory, the author put forward the early treatment rule of \"truncation and reversal\", and used to cleanse the \"poison\" and \"save Yin\" in the early stage of sepsis to quickly truncate the malignant development trend of sepsis. In the COVID-19 epidemic, we have found that patients with COVID-19 sepsis have \"acute deficiency syndrome\" in the early stage of clinical syndrome, which is an important factor leading to death. The clinical efficacy and mechanism of \"Shenhuang Granules\" in sepsis caused by non-novel coronavirus infection such as bacteria need to be further studied.",[186],"Sepsis",[186,188,189,190],"Shenhuang granules","Evidence-based evaluation","Effect mechanism research","2025-08-16",{"date":193,"type":38},"2025-08-22",{"date":195,"type":38},"2024-07-01",{"date":197,"type":22},"2026-07-01",{"name":44,"class":45},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":95},"100590250","treatment-of-transfusion-dependent-nonsevere-aplastic-anemia-with-luspatercept-a-multicenter-prospective-clinical-study-100590250","NCT06964971","Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n* 1.Age \\>= 18 years; 2.According to the \"Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition)\", the patient must be diagnosed with transfusion-dependent non-severe aplastic anemia (TD-NSAA) and meet the requirement of erythroid hyperplasia in bone marrow aspiration from the posterior iliac crest and\u002For sternum being more than 15%; 3.If not newly diagnosed with TD-NSAA, and there are combined primary disease maintenance medications, the following conditions must be met:\n\n  1. The patient has not received and does not consider HSCT or ATG treatment for at least the next six months;\n  2. If maintaining oral immunosuppressive therapy, the course must be at least 6 months and assessed as ineffective;\n  3. If maintaining androgen therapy, the course must be at least 3 months and assessed as ineffective;\n  4. If maintaining recombinant human erythropoietin therapy, the course must be at least 3 months and assessed as ineffective;\n  5. If maintaining thrombopoietin receptor agonist (TPO-RA) therapy, the duration must be \\>=6 months with confirmed inefficacy, and a washout period of \\>=1 month is required before study enrollment;\n  6. If the above maintenance medication durations are not met, a washout period of at least 1 month is required; 4.Serum ferritin level \\>= 1000 ng\u002Fml; 5.Complete whole exome sequencing and MDS\u002FAA next-generation sequencing testing are required.\n\nExclusion Criteria:\n\n* 1\\. Severe hepatic dysfunction (ALT or AST ≥ 3 × ULN); 2.Severe renal impairment (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or patients with end-stage renal disease); 3.Cardiac disease, including New York Heart Association (NYHA) Class 3 or higher heart failure, or severe arrhythmia requiring treatment, or recent myocardial infarction within 6 months of randomization; 4.Patients with uncontrolled hypertension, with controlled hypertension according to NCI CTCAE version 5.0 considered as ≤ Grade 1 for this protocol; 5.Patients with a PNH clone \\> 1%; 6.Patients planning to become pregnant or who are pregnant; 7.Surgical or clinical conditions that may significantly alter drug absorption, distribution, metabolism, or excretion (e.g., gastritis, ulcers, history of gastrointestinal or rectal bleeding; history of major gastrointestinal surgery); 8.Patients carrying congenital bone marrow failure-related gene mutations (homozygous or heterozygous, regardless of whether they are pathogenic\u002Fbenign\u002Flikely benign\u002F of uncertain significance).","80 Years",{"count":207,"type":22},90,[25],"The goal of this clinical trial is to learn whether Luspatercept alone or in combination with Deferasirox can promote hematopoietic function in patients with transfusion-dependent non-severe aplastic anemia, as well as to assess the safety and efficacy of this treatment approach.\n\nThe main questions it aims to answer is:\n\nwhether the combination therapy of Luspatercept and Deferasirox can improve hemoglobin levels in these patients.\n\nParticipants will receive Luspatercept every 3 to 5 weeks based on hemoglobin response, undergo complete blood counts every 1 to 3 weeks, and receive other necessary evaluations as required.",[211],"Transfusion-dependent Non-severe Aplastic Anemia","2025-05-07",{"date":214,"type":38},"2025-05-11",{"date":216,"type":22},"2025-05-20",{"date":218,"type":22},"2027-06-30",{"name":44,"class":45},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":228,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":95},"100581908","auricular-acupressure-for-perimenopausal-insomnia-100581908","NCT06856421","Auricular Acupressure for Perimenopausal Insomnia","Auricular Acupressure for Perimenopausal Insomnia: A Multicenter Randomized Controlled Clinical Trial","Acupressure","Inclusion Criteria:\n\n* Age between 45 and 55 years;\n\n  * Meetingperimenopause defined by the Staging of Reproductive Aging Workshop (STRAW);\n\n    * Patients must satisfy at least one diagnostic criterion for insomnia in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); ④ Nighttime sleep disturbances and associated perimenopausal symptoms persisting for at least 4 weeks; ⑤ No use, or stable long-term use (\\>2 months) of medications for treating insomnia;\n\n      * No prior auricular acupuncture therapy, good compliance, understanding of the study protocol, and signed informed consent.\n\nExclusion Criteria:\n\n* Does not meet inclusion criteria;\n\n  * Non-natural menopausal transition due to premature ovarian failure, drug intake, or surgeries (e.g., oophorectomy);\n\n    * Currently pregnant or breastfeeding;\n\n      * Insomnia caused by systemic diseases (e.g., stroke, Parkinson's disease, surgery, etc.);\n\n        * Presence of insomnia symptoms before the perimenopausal period;\n\n          * Infection in the areas near selected acupoints; ⑦ History of alcohol or substance abuse\u002Faddiction；\n\n            * Co-existing mental or psychological disorders (e.g., depression, generalized anxiety disorder, bipolar disorder, obsessive-compulsive disorder, etc.) or suicidal tendencies, in addition to insomnia; ⑨ Receipt of auricular acupuncture therapy within the past 3 months; ⑩ Participation in other clinical trials in the past 3 months;\n\n              * Any known chronic pain disorders that could affect sleep.","FEMALE","45 Years","55 Years",{"count":232,"type":22},160,[25],"This clinical trial aims to determine whether auricular Acupressure therapy can improve symptomatic insomnia in perimenopausal women.\n\nCan ear acupressure therapy significantly improve sleep quality in perimenopausal women with insomnia? What medical issues or adverse reactions might participants experience during the treatment? Researchers will compare ear acupressure therapy with traditional treatments in a control group to assess its effectiveness and safety.\n\nParticipants will:\n\nReceive auricular acupressure on Monday and Thursday, applying pressure for 3 consecutive days each week. This process will continue for 4 weeks, totaling 8 sessions.\n\nRecord assessment points as follows: Baseline (2 weeks before treatment to Week 0), mid-treatment (2 weeks after treatment begins), end of treatment (4 weeks after treatment begins), and follow-up (4 weeks after treatment ends) for primary and secondary outcome indicators. Eight weeks after treatment concludes, only the primary outcome indicator (Insomnia Severity Index) will be recorded.\n\nThis trial seeks to evaluate the potential benefits and safety profile of auricular acupressure therapy for managing insomnia in perimenopausal women.",[236],"Perimenopausal Insomnia",[236,238],"Auricular point","2025-04-26",{"date":241,"type":38},"2025-04-30",{"date":243,"type":22},"2025-06-01",{"date":172,"type":22},{"name":44,"class":45},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":252,"sex":17,"minAge":253,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100588866","clinical-study-on-the-use-of-massage-to-reconstruct-the-function-of-lumbar-stabilizer-muscles-and-improve-the-muscle-and-bone-imbalance-of-lumbar-disc-herniation-100588866","NCT06946979","Clinical Study on the Use of Massage to Reconstruct the Function of Lumbar Stabilizer Muscles and Improve the \"Muscle and Bone Imbalance\" of Lumbar Disc Herniation","Inclusion Criteria:\n\n* 1.Meet the diagnostic criteria for LDH as outlined in the ninth edition of \"Surgery,\" with confirmation via MRI;\n* 2.Age between 20 and 50;\n* 3.Simple L4\u002F5 disc herniation; VAS score ≥30\u002F100;\n* 4.Lumbar ODI index ≥20;\n* 5.No massage, acupuncture, or physical therapy within the past month;\n* 6.Signed informed consent form.\n\nExclusion Criteria:\n\n* 1: Exclusion criteria: history of spinal surgery or severe spinal trauma;\n* 2: combined with bone tuberculosis, tumors, severe osteoporosis, etc;\n* 3: combined with serious internal diseases such as cardiovascular, hematological, digestive system diseases, or psychiatric disorders;\n* 4: pregnant or lactating women;\n* 5: combined with autoimmune diseases, allergic diseases, acute or chronic infectious diseases accompanied by pain and joint dysfunction;\n* 6: MRI showing free nucleus pulposus or accompanied by cauda equina syndrome.",true,"20 Years","50 Years",{"count":256,"type":22},96,[25],"1. .Characterization of Stabilizing Muscle Dysfunction in LDH Patients Using advanced techniques such as high-density surface electromyography (HD-sEMG), this study will investigate the functional imbalance of lumbar stabilizing muscles in LDH patients by comparing their muscle function indicators to those of healthy controls.\n2. .Impact of Spinal Manipulation on Lumbar Stabilizing Muscle Function Through serial sEMG evaluations, the study will assess changes in stabilizing muscle function in LDH patients before and after spinal manipulation. This includes a focus on endurance, motor control, and reaction time, providing evidence to inform the application of spinal manipulation in LDH treatment.\n3. .Exploration of Mechanisms Underlying Spinal Manipulation in Improving \"Musculoskeletal Imbalance\" The study will examine correlations between improvements in stabilizing muscle function and clinical symptoms, such as pain relief and functional recovery. Statistical analyses of sEMG data and clinical efficacy indicators will be conducted to uncover the therapeutic characteristics of spinal manipulation in LDH intervention, offering new theoretical bases and strategies for long-term treatment and recurrence prevention.",[260],"Lumbar Disc Herniation","2025-04-19",{"date":263,"type":38},"2025-04-27",{"date":241,"type":22},{"date":266,"type":22},"2026-03-01",{"name":44,"class":45},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":252,"sex":17,"minAge":275,"maxAge":18,"enrollmentInfo":276,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":95},"100574348","central-motor-mechanisms-in-ais-via-hd-semg-eeg-and-neuromuscular-coupling-analysis-100574348","NCT06758115","Central Motor Mechanisms in AIS Via HD-sEMG, EEG and Neuromuscular Coupling Analysis","Study on the Central Motor Regulation Mechanism in Adolescent Idiopathic Scoliosis (AIS) Patients Based on HD-sEMG, EEG, and Neuromuscular Coupling Analysis","Inclusion Criteria:\n\n1. Patients aged ≥10 years;\n2. Risser sign grade 0-3;\n3. Cobb angle between 10° and 40°;\n4. No prior treatment;\n5. Female patients within 1 year after menarche or before menstruation;\n6. The patient's guardian signs the informed consent form for treatment.\n\nExclusion Criteria:\n\n1. Those who do not meet the diagnostic criteria for AIS or inclusion criteria;\n2. Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney, and hematopoietic system disorders, or those with mental illnesses;\n3. Patients with thrombocytopenia, coagulation disorders, or a tendency to bleed;\n4. Patients who are afraid of the treatment and cannot tolerate it;\n5. Those who have already received other treatments that may affect the study's outcome measures.","10 Years",{"count":277,"type":22},40,"OBSERVATIONAL","1. Verifying the Motor Control Effects of Spinal Manipulation on AIS Using outpatient and inpatient AIS patients from our department as the study subjects, standardized spinal manipulation treatment is applied. The efficacy is evaluated through a combination of clinical outcome measures, HD-EMG for paraspinal muscle function assessment, and Pro-Kin balance system for trunk stability analysis. This establishes an AIS efficacy platform to further clarify the effectiveness of spinal manipulation in motor control regulation of AIS.\n2. Investigating the Central Motor Network's Response to Spinal Manipulation in AIS Utilizing high-density sEMG-EEG technology, synchronized brain and muscle electrical signals are collected before and after treatment. By employing a neuromuscular synchronization and coupling analysis approach that integrates linear and nonlinear methods, the characteristic indices of information interaction between the central system and muscles are identified. This further explores the motor control and response characteristics of the muscle-cortex network to spinal manipulation in AIS.",[281],"Adolescent Idiopathic Scoliosis","2024-12-26",{"date":284,"type":38},"2025-01-03",{"date":286,"type":38},"2024-01-01",{"date":288,"type":22},"2026-12-31",{"name":44,"class":45},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":275,"maxAge":18,"enrollmentInfo":297,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":95},"100571232","3d-depth-camera-based-assessment-of-adolescent-idiopathic-scoliosisusing-a-depth-camera-100571232","NCT06717568","3D Depth Camera-Based Assessment of Adolescent Idiopathic ScoliosisUsing a Depth Camera","Assessment of Adolescent Idiopathic Scoliosis Based on 3D Imaging Technology Using a Depth Camera","Inclusion Criteria:\n\n(1) Adolescents aged 10-18 years, diagnosed with adolescent idiopathic scoliosis (AIS) with a Cobb angle ≥10°; (2) No history of spinal surgery or other corrective treatments; (3) Able to undergo short-term inpatient treatment (5 days) and comply with study procedures.\n\nExclusion Criteria:\n\n(1) Patients with congenital, neuromuscular, or other secondary scoliosis; (2) Presence of major comorbidities affecting spinal structure or muscle tone (e.g., spinal cord injury, muscular dystrophy); (3) Patients unable to complete standardized assessment procedures.",{"count":298,"type":22},80,"Adolescent Idiopathic Scoliosis (AIS) is a common spinal deformity affecting adolescent health, and early diagnosis and accurate assessment are crucial for preventing disease progression. Traditional assessment indicators, such as the trunk rotation angle (ATR) and Cobb angle, rely on clinical examinations and X-ray imaging, which have certain limitations, including radiation exposure and insufficient sensitivity. The Back Height Difference (BHD), as a quantitative measure of the back surface morphology, may reflect the degree of trunk deformity caused by scoliosis.\n\nThe use of the Kinect v2 depth camera to capture three-dimensional point cloud data of the back provides a high-precision, radiation-free assessment method.",[281],"2024-11-30",{"date":303,"type":38},"2024-12-05",{"date":305,"type":38},"2022-01-01",{"date":307,"type":22},"2024-12-31",{"name":44,"class":45},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":275,"maxAge":18,"enrollmentInfo":315,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":323,"locationsCount":95},"100565509","3d-imaging-assessment-of-scoliosis-back-height-difference-vs-trunk-rotation-angle-100565509","NCT06643104","3D Imaging Assessment of Scoliosis: Back Height Difference vs. Trunk Rotation Angle","Assessment of Adolescent Idiopathic Scoliosis Based on 3D Imaging With Depth Cameras: A Comparative Study of Back Height Difference and Angle of Trunk Rotation",{"count":298,"type":22},"This study focuses on adolescents with idiopathic scoliosis, employing 3D imaging technology with depth cameras to measure back height difference (BHD) and angle of trunk rotation (ATR) before and after conventional treatments such as massage, exercise therapy, and bracing. Statistical analyses are conducted to verify the correlation between BHD and ATR and to assess the sensitivity of BHD in evaluating short-term treatment effectiveness.",[281],"2024-10-13",{"date":320,"type":38},"2024-10-16",{"date":305,"type":38},{"date":307,"type":22},{"name":44,"class":45},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":252,"sex":17,"minAge":275,"maxAge":18,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":342,"locationsCount":95},"100554987","research-on-key-technologies-for-risk-prediction-and-precise-diagnosis-and-treatment-of-ais-based-on-epigene-phenotype-100554987","NCT06506227","Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype","Research on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of Adolescent Idiopathic Scoliosis Based on Epigene-phenotype","Inclusion Criteria:\n\n* Patients diagnosed with AIS;② Sex is not limited, age 10-18 years old; ③ Those who sign the informed consent and can cooperate with follow-up visits; ④ Those who can cooperate with X-ray, chemical test, genetic test and other examination and evaluation for the measurement of relevant indexes.\n\nExclusion Criteria:\n\n* Subjects with spine-related diseases such as Marfan's syndrome;\n\n  * Subjects with previous ankylosing spondylitis, spinal neurofibroma, spinal tuberculosis, spinal trauma and other spine-related diseases;\n\n    * Subjects with combined serious medical diseases and psychiatric patients;\n\n      * Those with ECOG score \\> 2, which may have an impact on the study results;\n\n        * Those who are affected by external factors such as economy, individualized differences, etc., so that they cannot complete the study.",{"count":332,"type":22},2000,[25],"Mining AIS biomarkers, elucidating the new mechanism of AIS pathogenicity, constructing risk prediction models, optimizing AIS precise diagnosis and treatment techniques, formulating precise diagnosis and treatment protocols and technical specifications for AIS combined with Chinese and Western medicine with independent intellectual property rights, and realizing the full coverage of Zhejiang Province by the end of 2026, so as to form the \"Zhejiang experience\" of AIS diagnosis and treatment.",[281],"2024-07-16",{"date":338,"type":38},"2024-07-17",{"date":340,"type":22},"2024-09-01",{"date":288,"type":22},{"name":44,"class":45},""]